|Bid||3.61 x 1800|
|Ask||3.66 x 1100|
|Day's Range||3.5200 - 3.7600|
|52 Week Range||1.2000 - 4.8660|
|Beta (3Y Monthly)||1.33|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar 18, 2019 - Mar 22, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||2.50|
Chiasma, Inc. (CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic diseases, today previewed anticipated upcoming corporate milestones and commented on the significant progress made by the company in 2018. “During 2018, we completed the required enrollment in both of our Phase 3 clinical trials of our investigational octreotide capsules product candidate, which we have conditionally trade-named Mycapssa®, and with those trials progressing as planned, we believe we have set the stage for a catalyst-rich 2019 including the announcement of topline data evaluating Mycapssa’s efficacy as potentially the first oral somatostatin analog for the maintenance therapy of adult acromegaly patients,” said Mark Fitzpatrick, President and Chief Executive Officer of Chiasma.
Every investor in Chiasma, Inc. (NASDAQ:CHMA) should be aware of the most powerful shareholder groups. Generally speaking, as a company grows, institutions will increase their ownership. Conversely, insiders often decrease Read More...
NEW YORK, Nov. 21, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
On a per-share basis, the Waltham, Massachusetts-based company said it had a loss of 31 cents. In the final minutes of trading on Thursday, the company's shares hit $4.20. A year ago, they were trading ...
Topline Data from Phase 3 CHIASMA OPTIMAL Trial of Octreotide Capsules, Conditionally Trade-Named MYCAPSSA®, Anticipated by September 2019 Company randomizes 80th patient.
Company continues to advance its novel octreotide capsules candidate through Phase 3 clinical trials in the U.S. and E.U. “Today, we acknowledge the acromegaly patients, their families and advocates, as well as the clinical thought leaders who have been instrumental in our efforts to develop an oral treatment alternative for this rare but serious disease,” said Mark Fitzpatrick, President and Chief Executive Officer of Chiasma.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Biotech stocks hitting 52-week highs on Oct. 1) Abbott Laboratories (NYSE: ABT ) AstraZeneca plc (NYSE: ...
If you’re interested in Chiasma Inc (NASDAQ:CHMA), then you might want to consider its beta (a measure of share price volatility) in order to understand how the stock could impactRead More...
The Waltham, Massachusetts-based company said it had a loss of 36 cents per share. In the final minutes of trading on Thursday, the company's shares hit $1.25. A year ago, they were trading at $1.45. _____ ...
Stock Monitor: Akebia Therapeutics Post Earnings Reporting LONDON, UK / ACCESSWIRE / March 20, 2018 / Active-Investors.com has just released a free research report on Chiasma, Inc. (NASDAQ: CHMA ). If ...
Examining Chiasma Inc’s (NASDAQ:CHMA) past track record of performance is a valuable exercise for investors. It enables us to understand whether the company has met or exceed expectations, which isRead More...